LY333328治疗实验性耐甲氧西林金黄色葡萄球菌心内膜炎的疗效。
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
作者信息
Kaatz G W, Seo S M, Aeschlimann J R, Houlihan H H, Mercier R C, Rybak M J
机构信息
Department of Internal Medicine, School of Medicine, Department of Veteran's Affairs Medical Center, Wayne State University, Detroit, Michigan 48201, USA.
出版信息
Antimicrob Agents Chemother. 1998 Apr;42(4):981-3. doi: 10.1128/AAC.42.4.981.
Abstract
The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.
摘要
通过使用左侧耐甲氧西林金黄色葡萄球菌心内膜炎的兔模型，将新型糖肽类抗生素LY333328的体内疗效与万古霉素进行了比较。动物分别接受LY333328或万古霉素（分别每24小时或8小时25mg/kg体重），持续4天。这些药物在清除菌血症以及减少赘生物和组织中的细菌数量方面同样有效。我们得出结论，在该模型中，LY333328在微生物学上是有效的，可能是万古霉素的一种治疗替代药物。
相似文献
1
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
Antimicrob Agents Chemother. 1998 Apr;42(4):981-3. doi: 10.1128/AAC.42.4.981.
2
Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
Infection. 1998 May-Jun;26(3):165-7. doi: 10.1007/BF02771843.
3
Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2005 Aug;49(8):3526-8. doi: 10.1128/AAC.49.8.3526-3528.2005.
4
Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2003 Sep;47(9):3002-4. doi: 10.1128/AAC.47.9.3002-3004.2003.
5
Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.
Antimicrob Agents Chemother. 1990 Nov;34(11):2081-5. doi: 10.1128/AAC.34.11.2081.
6
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 Jul;52(7):2538-43. doi: 10.1128/AAC.00510-07. Epub 2008 Apr 21.
7
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Antimicrob Agents Chemother. 2007 Sep;51(9):3397-400. doi: 10.1128/AAC.01242-06. Epub 2007 Jun 25.
8
Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
Antimicrob Agents Chemother. 1989 Apr;33(4):519-21. doi: 10.1128/AAC.33.4.519.
9
Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
Antimicrob Agents Chemother. 2005 Feb;49(2):857-9. doi: 10.1128/AAC.49.2.857-859.2005.
10
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
Antimicrob Agents Chemother. 1999 Jan;43(1):115-20. doi: 10.1128/AAC.43.1.115.
引用本文的文献
1
New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.
J Clin Med. 2023 Dec 14;12(24):7693. doi: 10.3390/jcm12247693.
2
Enhancing A82846B production by artificial attB-assisted overexpression of orf10-orf11 genes in Kibdelosporangium aridum SIPI-3927.
AMB Express. 2020 Mar 16;10(1):52. doi: 10.1186/s13568-020-00992-x.
3
Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.
Clin Microbiol Rev. 2019 Feb 13;32(2). doi: 10.1128/CMR.00041-18. Print 2019 Mar 20.
4
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
Infect Dis Ther. 2016 Mar;5(1):1-15. doi: 10.1007/s40121-016-0103-4. Epub 2016 Feb 1.
5
Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Drugs. 2015 Dec;75(18):2073-95. doi: 10.1007/s40265-015-0505-8.
6
Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.
Antimicrob Agents Chemother. 2015 Oct;59(10):6501-5. doi: 10.1128/AAC.00981-15. Epub 2015 Aug 3.
7
Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.
Infect Drug Resist. 2015 Jul 6;8:189-97. doi: 10.2147/IDR.S69412. eCollection 2015.
8
Oritavancin for acute bacterial skin and skin structure infections.
Expert Opin Pharmacother. 2015 May;16(7):1091-8. doi: 10.1517/14656566.2015.1026256. Epub 2015 Mar 24.
9
Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.
Core Evid. 2015 Feb 11;10:39-47. doi: 10.2147/CE.S51284. eCollection 2015.
10
New antimicrobial agents as therapy for resistant gram-positive cocci.
Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):3-15. doi: 10.1007/s10096-007-0389-y.
本文引用的文献
1
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
MMWR Morb Mortal Wkly Rep. 1997 Aug 22;46(33):765-6.
2
Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.
MMWR Morb Mortal Wkly Rep. 1997 Jul 11;46(27):624-6.
3
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. doi: 10.1128/AAC.41.6.1407.
4
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Antimicrob Agents Chemother. 1997 Jun;41(6):1307-12. doi: 10.1128/AAC.41.6.1307.
5
In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
Antimicrob Agents Chemother. 1997 Feb;41(2):488-93. doi: 10.1128/AAC.41.2.488.
6
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
Antimicrob Agents Chemother. 1996 Oct;40(10):2416-9. doi: 10.1128/AAC.40.10.2416.
7
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
8
Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.
Clin Infect Dis. 1993 Jun;16(6):750-5. doi: 10.1093/clind/16.6.750.
9
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.
Diagn Microbiol Infect Dis. 1995 Feb;21(2):85-93. doi: 10.1016/0732-8893(94)00147-o.
10
Automated fluorescence polarization immunoassay for monitoring vancomycin.
Ther Drug Monit. 1983;5(3):341-5. doi: 10.1097/00007691-198309000-00017.
Zotero 插件